




Searching News Database: United Therapeutics
HSMN NewsFeed - 11 Dec 2019
Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value
Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value
HSMN NewsFeed - 5 Aug 2019
CollPlant is Developing 3D-bioprinted Implants for Regeneration of Breast Tissue
CollPlant is Developing 3D-bioprinted Implants for Regeneration of Breast Tissue
HSMN NewsFeed - 20 Jun 2019
CollPlant Announces Corporate Name Change to CollPlant Biotechnologies to Better Reflect Its Business
CollPlant Announces Corporate Name Change to CollPlant Biotechnologies to Better Reflect Its Business
HSMN NewsFeed - 8 Apr 2019
United Therapeutics Announces BEAT Study of Esuberaprost Does Not Meet Primary Endpoint
United Therapeutics Announces BEAT Study of Esuberaprost Does Not Meet Primary Endpoint
HSMN NewsFeed - 2 Jan 2019
Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes
Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes
HSMN NewsFeed - 17 Sep 2018
Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate
Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate
HSMN NewsFeed - 4 Sep 2018
United Therapeutics And MannKind Announce Collaboration For Pulmonary Hypertension Products
United Therapeutics And MannKind Announce Collaboration For Pulmonary Hypertension Products
HSMN NewsFeed - 8 Aug 2018
United Therapeutics Announces FREEDOM-EV Study Of Orenitram Meets Primary Endpoint
United Therapeutics Announces FREEDOM-EV Study Of Orenitram Meets Primary Endpoint
HSMN NewsFeed - 20 Nov 2017
United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca(R)
United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca(R)
HSMN NewsFeed - 23 Oct 2017
United Therapeutics Announces FDA Approval of Third Generation Nebulizer for the Tyvaso(R) Inhalation System
United Therapeutics Announces FDA Approval of Third Generation Nebulizer for the Tyvaso(R) Inhalation System
HSMN NewsFeed - 12 Apr 2017
Respira Therapeutics Announces Collaboration with United Therapeutics to Treat Pulmonary Hypertension
Respira Therapeutics Announces Collaboration with United Therapeutics to Treat Pulmonary Hypertension
HSMN NewsFeed - 17 Dec 2014
United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change
United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change
HSMN NewsFeed - 5 Sep 2012
Third Critically Ill Patient Successfully Treated With Pluristem's PLX Cells Under Compassionate Use
Third Critically Ill Patient Successfully Treated With Pluristem's PLX Cells Under Compassionate Use
HSMN NewsFeed - 24 Aug 2011
FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint
FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint
HSMN NewsFeed - 26 May 2009
FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
HSMN NewsFeed - 16 Mar 2009
United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
HSMN NewsFeed - 17 Nov 2008
Lilly Licenses U.S. Rights for Tadalafil PAH Indication to United Therapeutics
Lilly Licenses U.S. Rights for Tadalafil PAH Indication to United Therapeutics
HSMN NewsFeed - 17 Nov 2008
FREEDOM-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint
FREEDOM-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint
HSMN NewsFeed - 30 Jun 2008
New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
HSMN NewsFeed - 1 Nov 2007
Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
HSMN NewsFeed - 16 Oct 2007
ViRexx Announces Second OvaRex(R) MAb Phase III Trial Reaches 118th Relapse Event
ViRexx Announces Second OvaRex(R) MAb Phase III Trial Reaches 118th Relapse Event
HSMN NewsFeed - 18 Apr 2007
Vasogen and Grupo Ferrer Form Collaboration to Commercialize Celacade(TM) in the European Union
Vasogen and Grupo Ferrer Form Collaboration to Commercialize Celacade(TM) in the European Union
HSMN NewsFeed - 27 Mar 2007
United Therapeutics and Mochida Pharmaceutical Sign Remodulin Distribution Agreement for Japan
United Therapeutics and Mochida Pharmaceutical Sign Remodulin Distribution Agreement for Japan
HSMN NewsFeed - 26 Feb 2007
United Therapeutics Announces Pulmonary Hypertension Opinion Leaders' Guidance On Intravenous Therapies
United Therapeutics Announces Pulmonary Hypertension Opinion Leaders' Guidance On Intravenous Therapies
HSMN NewsFeed - 12 Dec 2006
United Therapeutics Affiliate Initiates First-Ever Gene-Therapy Trial for Pulmonary Arterial Hypertension
United Therapeutics Affiliate Initiates First-Ever Gene-Therapy Trial for Pulmonary Arterial Hypertension
HSMN NewsFeed - 13 Oct 2006
Neurotechnology Industry Organization Launched to Advance Treatments for Brain and Nervous System Illnesses
Neurotechnology Industry Organization Launched to Advance Treatments for Brain and Nervous System Illnesses
Additional items found! 24

Members Archive contains
24 additional stories matching:
United Therapeutics
(Password required)
United Therapeutics
(Password required)